LEADER 01621nam  2200421 a 450 
001 9910695777503321
005 20070322102646.0
035   $a(CKB)5470000002372003
035   $a(OCoLC)86106712
035   $a(EXLCZ)995470000002372003
100   $a20070322d2007      ua             0
101 0 $aeng
135   $aurmn|---|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPrescription drugs$b[electronic resource] $eoversight of drug pricing in federal programs : testimony before the Committee on Oversight and Government Reform, House of Representatives /$fstatement of John E. Dicken
210  1$a[Washington, D.C.] :$cU.S. Government Accountability Office,$d[2007]
215   $a13 pages $cdigital, PDF file
225 1 $aTestimony ;$vGAO-07-481 T
300   $aTitle from title screen (viewed on Mar. 8, 2006).
300   $a"For release ... February 9, 2007."
300   $aPaper version available from: U.S. Government Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.
320   $aIncludes bibliographical references.
517   $aPrescription drugs 
606   $aDrugs$xPrices$zUnited States
606   $aMedicare
615  0$aDrugs$xPrices
615  0$aMedicare.
700   $aDicken$b John E$01382684
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Government Reform and Oversight.
712 02$aUnited States.$bGovernment Accountability Office.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910695777503321
996   $aPrescription drugs$93435639
997   $aUNINA